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Pharmaceutical Sciences

Detection of Surrogate M arkers after G am m a-hydroxybutyrate (GHB) Exposure
Chairperson: Mark Pershouse, Ph.D.
Gamma-hydroxybutyrate (GHB) is a substance naturally present in humans, as well as a
drug of abuse. The use of GHB in date-rape sexual assaults has increased over the past
few years. Currently different chromatography techniques are used to detect GHB in
blood or urine, with a detection timeframe of around 12 hours. This limited window of
detection causes many problems for law enforcement in preparing for these rape cases. In
this study microarray technology is used in a mouse model to detect biomarkers in
peripheral blood after GHB exposure. Epiregulin and Phosphoprotein enriched in
astrocytes 15 (Pea-15) both had increased expression in GHB dosed mice (Ig/kg) over
control. The detection of these genes RNA was confirmed using a semi-quantitative RTPCR assay. An intracellular flow cytometry assay was developed that could detect
protein changes in peripheral blood in both of these potential biomarkers after GHB
exposure. These results suggest that after further development, epiregulin and Pea-15
may prove to be significant surrogate markers in the indirect detection of GHB.
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Introduction

Gamma-hydroxybutyrate (GHB) is a powerful and rapidly active central nervous
system depressant. It is a naturally occurring substance in the brain, first synthetically
produced in 1960 as an anesthetic (Laborit, 1964). The majority of early research on
GHB investigated its anesthetic properties.
GHB is both a metabolite of gamma-aminobutyric acid (GABA) and a precursor
that can be degraded to produce a functional pool of G ABA. Because of their chemical
and metabolic relationship the two compounds have often been discussed and compared
to each other. Exogenously adm inistered GHB has many of the behavioral effects that are
tied to GAB A compounds, though many now consider GHB as a pharmacological entity
that is unique and may act as a neurotransmitter (Bemasconi et al., 1999; Howard and
Feigenbaum, 1997; M aitre, 1997; Tunnicliff, 1992; Vayer et al., 1987). W hether GHB
acts as a neurotransmitter or neuromodulator is still the subject of much controversy in
the literature.
GHB has recently been receiving more attention because of the potential
therapeutic affects but also because the incidence of abuse has increased. The euphoric
properties of GHB helped to foster the drug's emergence as a popular club drug in the
late 1990’s. In February o f 2000, after it was termed a drug of abuse and a date rape drug,
GHB was re-classified as a schedule I drug by the United States Drug Enforcement
Administration (2000).
This introduction covers the chemical, pharm acological, behavioral, and
toxicological background inform ation on GHB. This introduction will also discuss

m icroarray technology and the use of surrogate markers. Additionally, the overall
direction of this project will be presented.

M etabolism and Distribution
GHB is distributed in distinct regions of the brain. It is found in the substantia
nigra, striatum , hippocampus, and the frontal cortex. Higher concentrations of GHB have
been found in peripheral organs such as the heart, kidney, liver, muscle, and fat though
the biological significance o f these concentrations is not known.
The metabolism of gamma-aminobutyrate (GABA) provides the primary source
of GHB in the brain (Figure 1). This has been demonstrated by the administering of
radiolabeled GABA into the rat brain and measuring its conversion to labeled GHB (Roth
and Giarm an, 1969). GABA is deaminaled to succinic semialdehyde (SSA) by the
enzyme GA BA aminotransferase. The majority of SSA is converted to succinate and
used in the K reb’s cycle, but a small portion is converted to GHB by SSA reductase
(Cash et al., 1981 ; Gold and Roth, 1977). Experiments looking at the distribution of the
SSA reductase enzyme have shown that it is present only in the cytoplasm of neurons.
These neurons also contain the enzymes needed for the synthesis of GABA. It was
concluded that GHB formation occurs in neurons that are also able to synthesize GABA.
Other precursors to GHB in the brain and in peripheral organs are 1,4-butanediol
and gamm a-butyrolacetone. Both of these are present in the rat brain at 10% the levels of
GHB (Barker et al., 1985; Doherty et al., 1975). 1,4-butanediol is transformed rapidly
into GHB in the brain {Snead and Liu, 1984; Snead et al., 1982) while gammabutyrolacetone is probably m etabolized before entry in the brain, through the blood-brain
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Figure 1. Biosynthesis of GHB in brain
The main pathway for GHB synthesis is the metabolism of GABA. GABA is m etabolized
in the brain to succinic semialdehyde (SSA) and SSA eventually is broken down into
GHB. Another route for GHB synthesis is through the reduction of 1,4 butanediol or
gamma-butyrolactone. Both 1,4 butanediol and gamma-butyrolactone are present in low
concentrations com pared to GHB and GABA.

barrier by peripheral lactonases (Roth and Giarman, 1968). G am m a-butyrolactone has
been used in many pharmacological studies because it is absorbed m ore easily in the
body than GHB. It is also easier to obtain than GHB and can also be used as a drug of
abuse.
Once GHB has bound to a receptor, released, and the activity terminated by
uptake of the molecule from the synaptic cleft, it is then degraded. The degradative
pathway of GHB starts with GHB dehydrogenase converting it to SSA. The SSA is then
further broken down to succinate or GABA (Doherty et al., 1975; Kaufm an and Nelson,
1991; M ohler et al., 1976). The succinate is further metabolized into carbon dioxide and
water. The degradation of GHB into GABA can produce a functional pool of GABA
(Figure 2).

GHB binding To GHB receptor and relationship with GABA b receptors
Many studies have been conducted examining the binding of GHB to a receptor
so that pharmacological actions can take place. For years it was thought that GHB bound
to the GABA b receptors exclusively. Eventually, research showed that GHB bound to a
unique G-protein coupled receptor specific for the molecule (M aitre, 1997; Snead, 1994).
Snead measured radiolabelled GHB binding patterns in a rat brain by autoradiography.
He found that there was a different pattern of distribution of the labeled GHB from
labeled GABA binding. It was also determined that there are both high and low affinity
binding sites present in the brain. The GHB high affinity sites are absent from peripheral
tissues like the liver, kidney, muscle and heart, even though there are significant amounts
of endogenous levels of GHB in these organs (Snead and Liu, 1984). GHB-specific
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Figure 2. Degradation of GHB in brain
The main route o f GHB degradation is to succinic sem ialdehyde (SSA). SSA is then
converted to GABA or oxidized through the Krebs cycle. GHB can also be converted to
trans-hydroxycrotonate and further broken down through the Krebs cycle. The GABA
pool formed from this pathway can be released and bind to GABA b receptors. Before
degradation, the GHB can be released and bind to either the GHB receptor or GABA b
receptors.

binding sites appear to exist only on neurons in different locations throughout the brain.
Further evidence was gathered after the first antagonist for GHB binding (NCS-382) was
discovered (Maitre et al., 1990). M aitre's research showed that this antagonist blocked
GHB binding and many of the pharm acological and physiological effects of exogenous
GHB administration.
GHB s mode of action in the brain appears through dual mechanisms (Wong et
al., 2004). The neurobiological activity of GHB seems to be mediated through the GHB
receptor, while the pharm acological effects of exogenously administered GHB seems to
be partially mediated through the GABA b receptor. GHB may act directly on GABA b as
a partial agonist or indirectly on G A B A b receptor via GHB-derived GABA (Hechler et
al., 1997). Evidence supporting this hypothesis comes from studies showing minimal
binding of physiological levels of radiolabeled GHB to different GABA b receptor
isoforms that were overexpressed in cells. When higher concentrations of the labeled
GHB were used, there were low levels of binding to the GABA b receptors (Wu et al.,
2004). This premise was strengthened when GHB-sensitive and GHB-resistant rats were
dosed with GHB and baclofen (GABA agonist). Depending on dose, differences in motor
coordination between the two groups of rats led the authors to conclude that high
concentrations of GHB can lead to the activation of the GABAergic system (Lobina et
al., 2005).
It seems that endogenous levels of GHB do not bind to, or activate, the GABA b
receptors. The concentrations o f GHB needed to stimulate these receptors are much
higher than are found in the brain.

Release and m em brane transport o f GHB
It was determ ined that GHB plays a role in interneuronal signaling when it was
discovered that there was localized release after cellular depolarization. Brain slices
containing radiolabeled GHB gave results that were consistent with a depolarizationevoked and calcium -dependent release (Maitre et al., 1983; Maitre and M andel, 1982).
Since exogenous GHB can pass through the blood-brain barrier and also be
synthesized in the brain, an active transport system was postulated. It was discovered that
there was a high-affinity uptake system that was dependent on both sodium and chloride
ions (Benavides et al., 1982). Radiolabeled GHB accumulated in membrane vesicles in
the brain with a linear dependence on the sodium ion concentration. Though there is still
a small amount o f uptake in vesicles that do not contain either the sodium or chloride
ions, the ion’s presence marks a large rise in uptake.

Role o f GHB in brain function
Since GHB was synthesized as a substance to try and mimic GABA-like effects,
the majority o f early studies tried to understand the role of exogenous GHB activity.
Humans need large doses of GHB (20-40 grams) to receive the sedative or anesthetic
results, while endogenous levels of GHB in the brain are only in the 1-10 m icrom olar
range (Vayer and M aitre, 1988). The role of GHB in daily brain function has yet to be
determined.
The study o f specific neuronal responses to GHB is hindered because it is
metabolized to form GABA so rapidly. GHB administered to neuronal tissue {in vivo),
brain slices, or neural cells can lead to a GHB-specific response mediated through either

the GHB receptor or the stimulation of the GABAergic system depending on dose. Past
research has shown that low doses of GHB (micromolar range) can be blocked or reduced
by specific GHB receptor antagonists. There is no change in signal with GABA receptor
antagonists (Harris et al., 1989; Maitre et al., 1990; Osorio and Davidoff, 1979). Higher
doses of GHB (millimolar) result in a blocked signal when using GABA b antagonists
(W aldmeier, 1991 ; Xie and Smart, 1992). Other groups looked further into the GHB
effect on the GABA system by inhibiting the ability of GHB to be metabolized (Hechler
et al., 1997). W hen they inhibited the enzymes responsible for that action the formation
o f GABA from GHB was reduced. GHB was inhibited in displacing labeled GABA from
its binding sites on GABA b receptors, further indicating that GHB was not a specific
ligand for those receptors. These results have led many researchers to state that
exogenous GHB metabolism is able to produce enough GABA to effect GABAergic
signaling, but physiological levels of GHB have little affinity for the GABA b receptors.
Besides affecting the GABAergic system, exogenous GHB is known to affect the
dopaminergic system. GHB initially inhibits the release of dopamine. This results in an
accumulation of dopamine in presynaptic neurons (Hechler et al., 1991 ; Nissbrandt et al.,
1994; Roth et al., 1980). After high doses of GHB there is a rapid increase in dopamine
levels, followed by the release of this dopamine in certain regions of the brain (Hechler et
al., 1993). This increase in dopamine levels is very high, reaching between 6-10 times
baseline levels. Research has shown that changes in the dopamine system are regulated
through the GHB receptors but that the GABAergic system is indirectly involved
(Nissbrandt et al., 1994). These increases of dopaminergic activity may play a role in the
euphoric effects and abuse potential of GHB.
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It is also known that GHB affects the serotonin system, but w hether this is
through direct means or via another system (dopamine or GABA) is not known. GHB has
been shown to increase serotonin turnover rates without altering absolute levels (Hedner
and Lundborg, 1983; W aldm eier and Fehr, 1978). The mechanism for this is not known
but it is thought that it may have to do with the elevated tryptophan (precursor to
serotonin) levels associated with an increase in GHB levels (Maitre, 1997). Some
researchers believe that this control on serotonin turnover is the result of the affects of
GHB on the GABA system, since baclofen (GABA b agonist) has also been shown to
alter serotonin turnover (W aldmeier and Fehr, 1978). However, the distributions of
serotonin modulation are completely different between GHB and baclofen. This suggests
a unique mechanism may exist for the affect on serotonin from GHB (M aitre, 1997).

Behavioral pharm acology o f GHB
There have been many animal studies on the effects of GHB at the cellular level,
but relatively few concerning the behavioral effects of the drug based on the therapeutic
potential of GHB. The first behavioral effect found was anxiolytic effects. Given a non
sedative dose of GHB, mice showed a reduction in passive behaviors and increased
interaction with littermates (Krsiak et al., 1974). This is similar to the loss of inhibitions
humans show upon the ingestion of this drug. Further studies show that it is likely these
effects are mediated through either the conversion of GHB to GABA and the subsequent
binding to GABA a receptors (Hechler et al., 1997) or actual GHB stim ulation of GABA
release in certain sections o f the brain (Gobaille et al., 1999; Goodwin et al., 2005).
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There have also been studies looking at the reinforcing effects of self
administrated GHB preceding drug abuse. C olom bo’s group gave W istar rats the option
of water and a GHB solution. The rats always voluntarily consumed the GHB (Colombo
et aL, 1995a). Later, Colom bo’s group conducted experim ents with alcohol-preferring
rats (sP) and non-perferring (sNP) rats (Colombo et al., 1998). Presenting the GHB
solution for fourteen days as the only water source and later giving the choice between
the GHB solution and water both groups of rats showed an overwhelming preference for
the GHB solution after the two-week time frame. The research suggested that the
reinforcing properties of GHB were unmasked by the long time frame of GHB ingestion.
When they repeated this experiment they only presented the GHB solution for three days
instead of fourteen before giving the rats a choice. This time the sNP rats consumed very
low amounts of the GHB solution when given the choice, while the sP rats continued to
use large amounts of the GHB solution. The researchers theorized that the selectively
bred high alcohol preference rats (sP) possessed a genetically higher sensitivity to the
effects of alcohol, as well as GHB. They also concluded that GHB yields reinforcing
properties similar to those of alcohol and that the two drugs share sim ilar pathways at the
cellular level.

Therapeutic uses o f GHB
There are many potential therapeutic uses for GHB. It is currently being used for
the treatment of narcolepsy and alcohol withdrawal. Studies have also considered GHB
for the treatment of heroin dependence, anesthesia, anxiety, fibromyalgia, and other
medical problems.
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G H B ’s m ost important therapeutic use is to treat alcohol abuse. It has been used
successfully in Russia and W estern Europe for years to com bat the effects of alcoholism
and withdrawal symptoms, though this therapy has not been adopted in the United States.
GHB is effective in treating alcoholism because it reduces alcohol cravings and alleviates
the symptoms o f alcohol withdrawal (Addolorato et al., 2000; Gallim berti et al., 2000).
There are many pharmacological sim ilarities between the two drugs and it has been
proposed that GHB exerts its effects on alcohol dependence by duplicating the action of
alcohol in the central nervous system (Gessa et al., 2000).
Alcohol withdrawal can cause an increase in heart and respiratory rates, nausea,
depression, tremors, and seizures. Early studies looked at the ability of GHB to diminish
these symptoms in a dose dependent manner. W hen high doses of GHB (1 g/kg) are
administered, ethanol-dependent Sprague-Dawley rats were completely protected from
tremors and seizures (Fadda et al., 1989). Many other similar studies have looked at these
positive effects and all of them concluded that acute administration of GHB reduced the
affects of ethanol withdrawal.
The currently accepted hypothesis is that GHB exerts effects on ethanol
dependence through a substitution m echanism (Colombo et aL, 1995b). There have been
many observed pharmacological sim ilarities on which this argument is based. Both low
doses of GHB and ethanol have been reported to increase the release of dopamine in
certain regions of the brain (Cheramy et al., 1977; M aitre et al., 1990) as well as to
stimulate locom otor activity (Maitre, 1997). These findings are relevant because the
activation of the dopamine system and increased locomotor activity are common in the
reinforcing properties of drugs like alcohol (Bozarth, 1986; Wise and Bozarth, 1985). It

n

was also noted that doses of GHB producing anesthesia in naïve rats would only impose
low levels o f sedation in ethanol-dependant rats (Colombo et aL, 1995d). These reports of
cross-tolerance betw een GHB and ethanol suggest common neuronal changes by both
drugs and could impose a problem in the use of GHB as a therapeutic drug.
The potential for abusing GHB is also the subject of much interest in the
literature. M any studies have shown both a preference towards self-administration in rats
(Colombo et aL, 1995a; Colombo et aL, 1998; Colombo et aL, 1995c) and abuse by
human beings (Addolorato et aL, 2000); Centers for Disease Control, 1991; US Food and
Drug Adm inistration, 1991). These reports strengthen the idea that GHB possesses
reinforcing properties similar to ethanol. Another similarity of GHB to ethanol is that it
reduces anxiety. Many studies have looked at this property of alcohol (Becker and
Flaherty, 1982; Blanchard et aL, 1993; Colombo et aL, 1995d) and only a few with GHB
(Colombo et aL, 1998; Krsiak et aL, 1974). M easuring different levels of anti-anxiety
behavior, both groups concluded that consumption of GHB produces effects similar to
alcohol.
Because o f the research conducted on alcohol withdrawal, the effects of GHB on
the treatment o f heroin dependence became a focus of several studies (Gallimberti et aL,
1993; G allim berti et aL, 1994). G allim berti's group performed a study to see if GHB was
effective in suppressing withdrawal symptoms in heroin and methadone-dependent
patients. They found that after treatment with GHB for over one week, the addicts
showed fewer withdrawal symptoms than the placebo group. Their studies suggested the
efficiency of GHB in suppressing opiate withdrawal in humans. Another study failed to
demonstrate protection from opiate withdrawal symptoms by GHB (Rosen et aL, 1996).
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There were differences in the schedule and dosage of heroin; and this may explain the
differential response. Even though there are discrepancies in the studies there is enough
promising evidence to prom pt continued study into G H B 's efficiency in treating the
withdrawal symptoms o f heroin.
To legally purchase GHB, one must obtain a prescription (Xyrem) for the
treatment of narcolepsy. Narcolepsy is a rare sleep disorder whose symptoms include
excessive daytime sleepiness, sudden sleep attacks, sleep paralysis, hallucinations upon
falling asleep, and the temporary loss of muscle tone. All these symptoms are created
because of problems with REM sleep. The mechanism of narcolepsy is unknown, but
there has been a substantial amount of work done categorizing symptoms patients’
experience. Researchers believe these symptoms stem from the instability caused by both
REM and non-REM sleep, an increased number of awakenings and long periods of time
between sleep onset (M ontplaisir et al., 1978; Zarcone, 1973; Zorick et al., 1986). The
most common treatment for narcolepsy includes the use of a stimulant during the day to
hold off the sudden sleep attacks, and later, an anti-REM sleep agent to ward off the more
serious symptoms. The problem with this approach to treatment is the individual’s drug
tolerance, low com pliance, and a low level of effectiveness. GHB was initially
considered as a treatment for narcolepsy in the late 1970's (Broughton and M amelak,
1979). After treating sixteen narcoleptic patients, researchers found that GHB produced a
reduction in the severity o f the symptoms including limiting hallucinations and sleep
paralysis. They suggested that, GHB administered at night and certain amphetamine
analogs given during the day, reduced the major symptoms of narcolepsy. The largest
disadvantage of this treatment is the short duration of action requiring multiple
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administrations. There have been many follow-up studies that have come to the same
conclusion; GHB is an effective agent for the treatment of narcolepsy (Lamm ers et aL,
1993; M amelak et al., 1979; Scharf et al., 1985; Scrima et al., 1989; Scrima et al., 1990).
The mechanism by which GHB treats narcolepsy is not understood, but it is most
likely a cumulative effect o f many processes. First, the activation of GHB receptors is
known to produce the sedative or sleep-inducing effects. This is known because the
specific GHB antagonist NCS-382 can block this effect (Schmidt et al., 1991 ). GHB is
also known to improve REM sleep efficiency and decrease latency (Entholzner et al.,
1995; Lapierre et al., 1990). The GHB induced increase in opioid and dopamine response
could be a factor in the anti-depressant effects found in GHB-treated patients. GHB also
affects the release of acetylcholine, which has been implicated in animal models of
narcolepsy (Nishino et al., 1995; Nitz et al., 1995).
GHB has been studied for its anesthesia properties as early as the 1960’s and
these studies continue today. Early research concluded that GHB treatment resulted in
profound relaxation of jaw muscles, which helped facilitate upper airway surgery. There
was no depression in the circulatory system, no need for other analgesic agents, and no
major side effects (Solway and Sadove, 1965). Surgeries used in these studies have
ranged from gastrectomy, pneumonectomy (Solway and Sadove, 1965), coronary artery
bypass grafting (Kleinschmidt et al., 1997), and others. Despite a large amount of
positive data, widespread acceptance has eluded GHB as an analgesic. This may be
because of G H B ’s potentially addictive nature and its ability to produce seizures in
animals that resemble petit mal epilepsy (Tunnicliff, 1992).

The current accepted hypothesis for the m echanism of schizophrenia is increased
activity in the release of dopamine. While this theory has not been proven, there are
several links to the idea. Drugs that treat schizophrenia block dopamine receptors, while
drugs that increase dopaminergic activity usually aggravate symptoms. The interest in
GHB comes from its ability to regulate dopaminergic activity. GHB is known to have
conflicting effects on dopamine, causing both the stim ulation and inhibition of the firing
of dopamine. Some studies (Levy et al., 1983; Schulz et al., 1981) have looked into the
efficacy of GHB with schizophrenia patients. The overall results of these studies showed
that GHB had little to no antipsychotic effects and would not be helpful in the treatment
of schizophrenia patients.
There have been many other studies conducted to further document the
therapeutic effects of GHB, such as treatment for depression, anti-anxiety, and
fibromyalgia. A study was performed with thirty females suffering depression who were
injected with daily doses of GHB for 3-12 days. Depression severity was lowered in over
80% of patients (Rinaldi et al., 1967). As yet, there has been no follow up to this study
and GHB is not used as an antidepressant today. GHB has also been tested as an anti
anxiety drug. Studies have shown that GHB can decrease anxiety and bring a level of
calmness to subjects (Addolorato et al., 1999; Ferrara et al., 1999). The symptoms of
fibromyalgia include chronic fatigue, muscular-skeleton pain, and non-restorative sleep.
These symptoms are found in an estimated 2% of Americans (Wolfe et al., 1995). When
GHB was administered to afflicted patients there was a significant decrease in the
severity of the problem (Scharf et al., 1998). The m echanism involved is unknown, but it
may be connected to the ability of GHB to increase slow -wave sleep.
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Abuse Potential and Toxicology ofG H B
GHB is absorbed rapidly and the onset of action is approximately fifteen minutes
after ingestion (Vickers, 1969). Adverse effects associated with GHB are dosedependent. Small doses (10 mg/kg) can cause euphoria, amnesia, nausea, vomiting,
dizziness, confusion, drowsiness, and a lowered respiratory state. Large doses of the drug
(50 mg/kg) can cause unconsciousness, coma, or death. These negative effects are
produced from respiratory depression and can be difficult to treat. In fact, there is no real
treatment for a GHB overdose. Supportive care is the usual action, since the effects of
GHB toxicity usually wear off in a m atter of hours. Physostigmine has been used in the
past as a potential drug in treating GHB-related comas (Yates and Viera, 2000). The
effectiveness of this treatment has recently been challenged in a new study that warned
that physostigmine does not always arouse coma patients, but can cause physostigmine
related toxicity (Bania and Chu, 2005). This drug acts as an acetlycholinesterase inhibitor
and thus potentiates cholinergic transmission. These mechanisms are not clear, except
that since GHB is a CNS depressant, the activation of the cholinergic system by
physostigmine, should increase the excitatory pathways enough to overcome the
inhibition from GHB.
GHB has been tested for genotoxicity in erythrocytes in the peripheral blood of
mice (Dass and Ali, 2004). This study showed that GHB does not seem to be genotoxic,
but future work m ust be done to assess any potential carcinogenicity. There is no
evidence of tolerance, withdrawal, or physical dependence when GHB is used at or near
therapeutic levels (3.5 g/day). M ultiple studies of humans and rodents have supported
these results (Addolorato et al., 2005; Addolorato et al., 1996; M aitre, 1997)). However,

IR

there are reports of high volume, chronic users o f the drug that have produced withdrawal
symptoms sim ilar to that o f alcohol (Craig et al., 2000; M iotto et al., 2001). In 2000, the
increased abuse of GHB led the DEA to re-classify the drug as a schedule 1 substance
( 2000 ).

Prevalence in Society Today
The prevalence o f GHB in drug-facilitated rape is increasing and is now the most
common substance used for this purpose (NDIC-2003 National Drug Threat
Assessment). Drug facilitated rape or date rape occurs when the victim is physically
unable to consent to a sexual activity. The ability of GHB to mentally and physically
incapacitate a victim is further intensified when combined with alcohol. The combination
of GHB and alcohol can cause an increased effect of symptoms during the time the
alcohol is present in the body as compared to the effect of GHB alone (McCabe et al.,
1971). GHB is quickly metabolized in the body by oxidative enzymes and the eventual
byproducts are carbon dioxide and water. W ith rapid degradation, and no metabolite
present, detecting this drug in victims is a serious problem. Many victims will not report
an assault until days afterwards because of memory lapses or the physiological trauma
associated with such an event. GHB is detectable in a person’s system for only a limited
amount of time; twelve hours in the urine (Kavanagh et al., 2001 ) and eight hours in
blood (Ferrara et al., 1993) using currently available techniques. The most popular
method so far is the use of gas chromatography-mass spectrometry (GC-MS) after the
drug is extracted from the sample. New detection techniques are beginning to be
developed that low er the sample preparation time and increase the sensitivity using both
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G C-M S, liquid chrom atography-tandem mass spectrometry, and capillary
electrophoresis-electrospray ionization ion-trap mass spectrometry (Crookes et al., 2004;
G ottardo et al., 2004; W ood et al., 2004)). W ith a window of less than 24 hours for
detection of GHB, many perpetrators are acquitted for lack of evidence that the victim
was drugged. This problem will be solved only by continued improvements in
chrom atography technology or new approaches to developing a test for the detection of
GHB.

M icroArray Technology
M icroarray analysis has become such a valuable technique because it generates
useful data for the expression of thousands of well-annotated genes in a manner of days.
Previously, this was either logistically impossible, or would have taken years of
experiments. W hile microarray analysis was originally dismissed as unfocused, this bias
is dissipating due to the realization that understanding a molecule, in this study GHB, in
the context of its interactions with thousands of other genes, requires a high-throughput
approach. The strength of a discovery-driven approach is that the results are not limited
by the scope of an investigator’s expectations. Results are often found that are
unexpected and potentially more valuable than the expected results.
M odem microarrays contain 50-70 base pair long oligonucleotides designed to
specifically detect thousands of RNA transcripts. Each spot on a chip correlates with a
specific probe, and each probe corresponds to a specific gene transcript. These
oligonucleotides are spotted multiple times on a chip to assess intra-array variability. The
labeled pools of cDNA are then incubated with the slides and specifically bound to the
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oligonucleotides. The fluorescent signal intensity is detected and this signal is indicative
of the relative expression level of the gene versus control.
One concern with microarray experiments is the design of the experim ents
themselves. This procedure is often too expensive, time consuming, and requires m ore
material than one tissue or animal yields. Pooling of samples from like animals can be
done in some experimental designs. There are at least two types of pooling, com plete and
sub-pooling (Peng et al., 2003). Complete pooling occurs when all of the samples from
one treatment group are pooled onto one array and the array is hybridized only once. This
approach cannot be used for statistical analysis, but can be used to focus on potential
targets or genes important to the treatment. Sub-pooling is similar to complete pooling
except multiple arrays are used within each group. This addresses the variability found
among array experiments. This approach can be used in statistical microarray
experiments and is much more thorough, but it is also more expensive, time-consuming,
and analysis is much more difficult. The experimental approach depends on the focus and
aim of the study. This study used the complete pooling method. Some arrays were
duplicated and the results from the genes of interest were consistent. Even after
considering these potential concerns there is no other technology available that is as
powerful and or rapid at uncovering novel biomarkers. This method provides a unique
opportunity to identify thousands of genes expressed simultaneously in one set of
experiments that can be directly compared.
The use of microarray technology to determine biomarkers is gaining acceptance
in many different fields. Biomarkers are defined as a laboratory measurement that reflects
the activity o f a disease or drug process (Katz, 2004). Many studies have been conducted
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to find markers for alcohol abuse (Chen et al., 2003; Helander, 2003; Montalto and Bean,
2003). These biomarkers have helped improve on knowledge of drinking patterns for
treatment, m onitored abstinence in outpatient treatment, and identified individuals at risk
of alcohol abuse. Appropriate use o f biochemical markers will facilitate early
intervention and successful m anagem ent of patients with alcohol use disorders.
Biomarkers have also been developed to study the effects of heroin, cocaine, nicotine,
and methamphetamines abuse (Al-Amri et al., 2004; Benowitz et al., 2003; Brenneisen et
al., 2002; Elkashef and Vocci, 2003; Garcia-Fuster et a l, 2003; Ishigami et a l, 2003;
Underner et a l , 2004; W iesner et a l, 2004). By measuring apomorphine, researchers can
assess central dopamine system alterations that are associated with chronic heroin
consumption (Guardia et a l , 2002). Other researchers have looked through
neuroendocrine and neuroimaging studies to identify specific biological markers that
could be used to characterize genes that are activated among chronic cocaine users
(Elkashef and Vocci, 2003). In cancer diagnosis and treatment many surrogate markers
have been discovered, and are currently being developed (Alvaro et a l, 2005; Blay et a l,
2005; Schmitt et a l, 2004; Van den Eynden et a l, 2004). Inflamm atory breast cancer is
an aggressive form of cancer with poor detection and prognosis. Surrogate markers such
as the overexpression of E-Cadherin and RhoC GTPase proteins in breast tissue have
been developed and are currently being used in laboratories (Van den Eynden et a l,
2004). This is a relatively new field but one that is rapidly gaining acceptance.
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Specific Aims

My hypothesis is that GHB will induce gene expression changes in a mouse
model and these changes will be correlated with the time interval post exposure. In other
words, GHB will induce acute gene expression changes that moderate over time. These
gene expression changes may be of a longer duration than the time it takes to metabolize
GHB, thus improving our window of detection.
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Materials and Methods
Mice
Female DBA/2J mice (7-8 weeks old) were obtained from The Jackson Laboratory (Bar
Harbor, ME) and housed one week before GHB treatment, with a 12-hour light/dark
cycle. The mice were m aintained with 3 mice per cage and had access to mouse chow
and water continuously. Anim als used in this study were maintained in facilities
consistent with the guidelines o f American Association for the Accreditation of
Laboratory Animal Care (AAA-LAC) and the Institutional Animal Care and Use
Committee (lUCUC).

Administration o f GHB and Blood Isolation
GHB (4-Hydroxybutyric acid sodium salt, Sigma-Aldrich, St Louis, MO) was kindly
provided by the State of M ontana Crime Lab. GHB was dissolved in distilled water (213
mg/ml) and injected intraperitoneally at a single dose of 1 g/kg. The injection size was
7.5 ml/kg per mouse. Animals were sacrificed on day 1,2, 4, or 7 post-injection by C 0 2
affiliation and exsanguinated by cardiac puncture. Blood used in microarrays was
immediately frozen in liquid nitrogen, while blood used for RT-PCR or Flow Cytometer
assays was placed in ice and immediately processed.

M icroarray Experim ents
RNA Isolation
Blood was pooled within the groups by days post-injection and total RNA was isolated
using QIAamp RN A Blood M ini Kit (Qiagen, Valencia, CA). Brain tissue samples were
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processed by Polytron hom ogenization in the presence of TRIzol reagent. RNA is then
isolated follow ing the m anufacturer’s protocol (GIBCO BRL, Grand Island, NY).
A dditional purification o f the total RNA population was performed using the RNeasy kit
(Qiagen, V alencia, CA). RNA quality is assessed by absorbance at 260/280 nm.

RNA Am plification
RiboAmp RN A Amplification Kit (Arcturus Biosciences, M ountain View, CA) was used
to amplify the blood total RNA to high yields of aRNA. An average of 500-600 ng of
total RN A was used perform a single round of amplification and the yield averaged 10 pg
of mRNA.

Mouse ÎOK Microarrays
M icroarray Array A oligonucleotides were purchased from MWG Biotech (High Point,
NC) and consisted of 9853 mouse genes. The genes are represented by 50 bp oligos
designed to specifically detect the gene of interest. The arrays also include 104
Arabidopsis controls. The represented genes were selected from various databases (e.g.
EBI, NCBI, Ensembl, GoldenPath) and kept non-redundant in M W G’s proprietary
CodeSeq® database. Alm ost all genes on Array A have a known function or clearly
defined protein domains.

Target Labeling and Hybridization
Labeled targets are made by incorporating aminoallyl-labeled dUTP (Ares Labeling Kit,
M olecular Probes Inc., Eugene, OR) during first strand synthesis using 2 pg of amplified
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RNA as tem plate, reverse transcriptase (Superscript II, GIBCO BRL, Grand Island, NY )
and oligo dT (18) primers. Ares A lexaFluor 555 and AlexaFluor 647 dyes (M olecular
Probes, Eugene, OR) are added by covalent attachment to the amino allyl group
according to the m anufacturer’s protocol, and incubated for 60 minutes at room
temperature. To insure sufficient labeling, the levels of the labeled cDNA were measured
by spectrophotom eter (Nanodrop, ) before hybridization. The experimental or control
target and the reference target were mixed and hybridized to the array at 46°C for 16
hours in a hybridization chamber. Arrays were washed once in 1 X SSC and 0.01% SDS,
twice in IX SSC, and twice in lOmM TE, then dried by centrifugation in a tabletop
centrifuge fitted with a plate spinning rotor.

MicroArray Scanning and Analysis
The processed microarray is read with an Axon GenePix 4000B laser slide scanner. This
scanner was fitted with two excitation lasers (532 nm and 635 nm) permitting
simultaneous scanning o f two color data without the need for multiple image registration.
GenePix Pro 4.0 software was used to perform automatic delineation of spot boundaries,
measurement o f local background for each spot, and digitization of fluorescence intensity
on the microarray. Tabular data was exported to GeneTraffic Duo Microarray Data
M anagement and Analysis Software (lobion Informatics, LLC, La Jolla, CA).
GeneTraffic integrates the data and image files from GenePix into a browser-based
interface that connects to an on-site Linux server. The software provides the user with an
easy to use system for normalization, analysis, data backup and storage. The scanning
parameters for successful array spots were set based on fluorescence intensity and
detection levels. The brightest spots were adjusted to be at or Just below saturation of the
detector. Array spots with obvious defects were tagged and excluded from subsequent
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analyses. Norm alization was performed based on total red and green dye intensity levels
throughout the spots on the array. This normalization com pensates for differences in
signal intensity based on extraction or labeling differences betw een samples. The
fluorescence intensity values were log-transformed and replicates of the identical samples
were checked for analogous readings. Ratios of gene expression for each feature (gene)
were filtered to limit analysis to those outside of intra-array and experimentally induced
variance. Genes that alter their expression between test populations and control by a
factor of 2 (50% decrease or 100% increase) were then considered for confirmation by
RT-PCR.

Semi-quantitative RT-PCR
The expression levels of epiregulin and P ea-15 mRNA were analyzed using reverse
transcription-PCR method. Total RNA was isolated using QIAam p RNA Blood Mini Kit
(Qiagen, Valencia, CA) from peripheral blood. The reverse transcription contained 50 ng
RNA, oligo-dT prim er and followed the protocol of Sensiscript RT (Qiagen, Valencia,
CA). The cDNA was then subjected to gene-specific PCR.
Primer Name

Sequence

Size

Annealing

Cycles

Temperature
Pea-15 (+)

5 ' -CCGTCCTGACCTCCTC ACTAT-3 '

233 bp.

Pea-15 (-)

5 ’-GG AAGGGAGTGGTCTG ATG A A -3 ’

—

Epiregulin(+)

5 -ACACTGGTCTGCGATGTGAGC-3 '

195 bp.

Epiregulin(-)

5 ’-TCCCCTG AGGTC ACTCTCTC A -3 ’

—

P-actin (-K)

5 '-TTCTTTGCAGCTCCTTCGTTGCCG-3 '

457 bp.

P-actin (-)

5 ' -TGG ATGGCTACGTAC ATGGCTGGG-3 '

—
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61

29
—

64
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—

----

—

--

Through electrophoresis, the amplified PCR product was resolved on a 10%
polyacrylamide gel, stained with ethidium brom ide, and the intensities were measured
using the NIH Image Analysis program. The ratio of the gene of interest divided by the
P-actin control was then determined. This ratio was log transformed and this data is
presented.

Flow Cytometer
Peripheral blood was collected in a tube with ED TA (5mM final concentration). Whole
blood (50p.l) was added to 250 p,l erythrocyte lysis Buffer EL (Qiagen, Valencia, CA).
Cells were then washed two times with PAB (IX PBS, 1% BSA, 0.1% sodium azide).
Cells were then fixed with a final concentration of 1.6% formaldehyde (Calbiochem, La
Jolla, CA) for 10 minutes at room tem perature and washed with PAB. The cells were
then permeabilized with ice-cold methanol (J.T. Baker, Phillipsburg, NJ) for 15 minutes
on ice and again washed with PAB. Cells were then incubated with 50 yd RatIgG (600
p.g/ml) for 10 minutes on ice to block the Fc receptors and then washed with PAB. Goat
anti-epiregulin antibody (1.5 pg) (R&D Systems, M inneapolis, MN) or goat anti-mouse
Pea-15 (1.7 pg) (Santa Cruz Biotechnology, Santa Cruz, CA) was added and incubated
on ice for 40 minutes. Cells were washed with PAB, resuspended, and then incubated
with fluorescein isothiocyanate (FITC)-conjugated donkey anti-goat Alexa flour 488
(Molecular Probes, Eugene, OR) for 20 m inutes on ice. As a control, cells were incubated
with anti-mouse CD45 (BD Biosciences Pharmingen, San Diego, CA), Epiregulin
antibody pre-incubated with recom binant epiregulin (R&D Systems), or P ea-15 antibody
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pre-incubated with a specific blocking peptide (Santa Cruz Technology). The cells were
then washed two times with PAB. The labeled cells were analyzed on a Becton
Dickenson FACSaria flow cytom eter.

Statistical M ethods
Statistical analysis was done using the software package PRISM, v. 3.03 (Graphpad, San
Diego, CA) and Excel. D ifferences between control and GHB treated mouse groups in
the flow cytom eter experim ents were assessed using a paired two-tailed t-test after the
data was normalized to percent control. Differences between control and GHB treated
mouse groups in the RT-PCR experiments were assessed using a paired two-tailed t-test
after the log of the ratio betw een the gene specific band and the (3-actin control band was
determined. All values are reported as mean 4-/-SEM; P<0.01 and P<0.05 were
considered significant.
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Results

M icroarray
M icroarray technology was used to identify potential gene expression changes in
peripheral blood from GHB injected DBA/2J mice. Total RNA was obtained from blood
that was extracted from four GHB injected mice and pooled for each of the three timepoints. There were also three saline injected control mice pooled for each of the timepoints. Using the Mouse lOK Array set A from MWG we found nine genes that passed
through the arbitrary cutoff 24 hours after a single acute GHB injection. Phosphoprotein
enriched in Astrocytes 15 (P ea-15) showed a 20.9-fold increase in samples from day 1
mice, an 8.5 fold increase in samples from day 4 mice, and a return to background levels
by day 7 in those samples. Epiregulin increased 19.2-fold in day 1, 4.6-fold by day 4, and
below control levels by day 7. O ther genes that showed a large expression increase over
control in day 1 mice were Dopamine receptor 2, Cholinergic receptor-muscarinic 3,
Galanin, N ucleolar protein family A, Neurotensin receptor 2, Colony stimulating factor 2
receptor, and Histidine decarboxylase (Table 1). Based on the large increases of P ea-15
and epiregulin expression through 4 days post-GHB injection it was determined to look
further at the affect of GHB on these genes.
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TA BLE 1
UNIQID
Activated genes
N M _008556
N M _007950
N M _033269
N M _ 0 10077
N M _010253
NM _026578
N M _008747
N M _007780
N M _008230

Nam e

D ayl

Day4

Day7

Phosphoprotein enriched astroeytes 15 (Pea-15)
Epiregulin (Ereg)
Cholinergic Receptor,M uscarinic 3 (Chrm3)
Dopam ine Receptor 2 (Drd2)
Galanin (Gai)
Nucleolar protein fam ily A (N o la l)
Neurotensin receptor 2 (Ntsr2)
C olony Stimulating factor 2 receptor (C sf2rbl)
Histidine Decarboxylase (Hdc)

20.9
19.2
8.0
7.8
6.5
5.5
5.0
4.9
4.5

8.5
4.6
3.8
.1
N /A
3.2
N /A
2.8
3.1

.05
-1.1
-.07
.02
.03
1.1
-.1
,03
-.24

-2.53
-2.3
-1.8

-1.58
-1.37
-1.52

-1.39
-1.3
-1.23

Suppressed Genes
NM^O 19578
E xostoses (m ultiple)-like 1 (E xtll)
Mitochondrial Ribosomal protein L17 (M rpll7)
NM „025301
Solute carrier family 7 transporter (Slc7a5)
NM^Ol 1404

Semi-quantitative RT-PCR
Sem i-quantitative reverse transcription PCR (RT-PCR) was used to confirm the
microarray data. Using gene specific primers, along with control prim ers (|3-actin),
differences in total mRNA levels can be distinguished. Total RNA was extracted from
white blood cells and analyzed. Conditions were determined so that the gene specific RTPCR product was still in the linear phase when the comparisons betw een that product and
the control product were made. There were increased levels of Epiregulin expression in
GHB injected mice (.4733 -t-/- ,06) over the saline control group (.2857 +/- .05) after Day
1 (Figure 3). This increase lasted through the Day 2 experimental groups (GHB= .4324
-I-/-

.067 and control^ .2564

-t-/-

.067) while by Day 4 there were small detectable changes

between the groups (GHB= .2307 +/- .063 and control^ .2784 4-/- .05). While there were
changes between the two groups they fall out of the statistical significant range.
P ea-15 expression was also increased through Day 1 (GHB= .1637 +1- .01 and
control= .0339 4- / - .009) and Day 2 (GHB= .2053 4- / - .03 and control= .0614 4- / - .003),
while declining to control levels by Day 4 (GHB= .3035 +/- .06 and control^ .2577 +/.0024) (Figure 4).
The experimental design included 6 GHB-inJected mice that were pooled into 3
groups during a timeframe of 24, 48, and 96 hours. Four saline-injected control mice
were pooled into 2 groups during a timeframe of 24, 48, and 96 hours. All experiments
were performed at least 2 times.
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Figure 3. Epiregulin Semi-quantitative RT-PCR
(a) Representation o f Epiregulin Semi-Quantitative RT-PCR experiment, (b) Densities of
bands were averaged from all experiments after background was subtracted. The ratio of
Epiregulin/p-actin bands was determined and the log of that ratio was used in graph. Data
is presented as the mean 4-/- SEM. Samples 1-3, day 1 GHB-treated mice; sample 4, day
1 Control mice; m olecular weight ladder; sample 5-7, day 2 GHB-treated mice; sample 89, day 2 Control mice; samples 10-12, day 4 G H B-treated mice; samples 13-14, day 4,
Control mice.
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FIGURE 4
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Figure 4. Pea-15 Semi-quantitative RT-PCR
(a) Representation of Pea-15 Sem i-Quantitative RT-PCR experiment, (b) Densities of
bands were averaged from all experiments and background was subtracted. The ratio of
Pea-15/p-actin bands was determ ined and the log of that ratio was used in graph. Data is
presented as the mean -h/- SEM. *(p<0.05 using t-test). Samples 1-3, day 1 GHB-treated
mice; sample 4-5, day 1 Control mice; molecular weight ladder; sample 6-8, day 2 GHBtreated mice; sample 9-10, day 2 Control mice; samples 11-13, day 4 GHB-treated mice;
molecular weight ladder; sam ples 14-15, day 4 Control mice.
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Intracellular Protein Staining
An intracellular flow cytom eter assay was developed to look for protein
differences betw een the GHB- treated and saline-treated control groups. Epiregulin was
expressed both on the cell membrane and in the cytoplasm. Pea-15, however, is only
found in the cytoplasm . This assay enabled us to use specific antibodies to detect the
proteins in form aldehyde fixed white blood cells.
Epiregulin protein levels in GHB-treated mice were increased (256% -t-/- 39.6)
over control 24 hours after injection (Figure 5). There was a smaller but statistically
significant increase detected after day 2 (163% +!- 11), while levels returned to near
baseline by day 4 (127% +/- 12). Co-incubation with a CD-45 specific lymphocytespecific m arker determined that the epiregulin antibody specifically stained white blood
cells (Figure 6). Next, it was important to see if the antibodies were binding specifically
to their respective proteins in the cell. Recombinant epiregulin protein was pre-incubated
with the epiregulin antibody and blocked antibody binding by 67% (Figure 9a).
Pea-15 protein levels in GHB mice were increased (213% +/- 30.3) over control
24 hours after injection (Figure 7). Pea-15 levels were still increased after day 2 (208%
+/- 32.2), while levels were near percent control by day 4 ( 112% +/- 6.6). Using a CD-45
lymphocyte specific marker it was determ ined that the Pea-15 antibody specifically
stained white blood cells (Figure 8). A blocking peptide was used in correlation with the
Pea-15 antibody to inhibit 54% -75% of antibody binding as assessed by median
fluorescence (Figure 9b).
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Figure 5. Epiregulin Specific Staining
(A) Overlay o f background fluorescence from secondary antibody, epiregulin binding on
control W BC and the population shift of epiregulin detection in GHB treated WBC. (B)
Detection o f both the intracellular and the membrane surface Epiregulin protein on white
blood cells isolated from GHB treated mice and control. GHB treated mice (n=10) and
control mice (n=7) were exam ined at 24 hours after exposure. GHB treated mice (n=7)
and control mice (n=5) were also examined after 48 hours. After 96 hours protein levels
were also determ ined in GHB (n=7) and control (n=5) mice. The FITC median intensity
was measured on all samples. Data are presented as percent of control mean +/- SEM.
**(p<0.01 using t-test)
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FIGURE 6
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Figure 6. Epiregulin and CD45 Isotype Staining
Example of cells stained with both the CD45 isotype and the epiregulin specific antibody.
(A) Illustration of side scatter vs. forward scatter. (B) CD45 isotype staining vs. protein
specific staining. (C) Histogram of total FITC protein specific staining. (D) Diagram
illustrating the histogram of CD45 isotype staining. This specificity dem onstrates that
between 90-98% o f the FITC signal was derived from CD45 positive cells.
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FIGURE 7
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D a y 4 GHB

Figure 7. Pea-15 Specific Staining
(A) Overlay of background fluorescence from secondary antibody. P ea-15 binding on
control W BC and the population shift of P ea-15 detection in GHB treated WBC. (B)
Detection of intracellular P ea-15 protein on white blood cells isolated from GHB treated
mice and control. GHB treated mice (n=10) and control mice (n=7) were examined at 24
hours after exposure. GHB treated mice (n=7) and control mice (n=5) were also
examined after 48 hours. After 96 hours protein levels were also determined in GHBtreated (n=7) and control (n=5) mice. The FITC median intensity was measured on all
samples. Data are presented as percent of control of mean +/- SEM. **(p<0.01 using ttest) and *(p<0.05 using t-test)
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1 00 0 0

100 0 0 0

Figure 8. Pea-15 and CD45 Isotype Staining
Example of cells stained with both the CD45 isotype antibody and the P ea-15 specific
antibody. (A) Illustration of side scatter vs. forward scatter. (B) CD45 isotype staining vs.
protein specific staining. (C) H istogram of total FITC protein specific staining. (D)
Diagram illustrating the histogram of CD45 isotype staining. This specificity
demonstrates that between 90-98% of the FITC signal was derived from CD45 positive
cells.
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FIGURE 9
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Figure 9. Antibody Specific Staining for Epiregulin and Pea-15
(A) R ecom binant epiregulin blocks epiregulin antibody binding on white blood cells. (B)
P ea-15 blocking peptide inhibits P ea-15 antibody binding on white blood cells. Antibody
specificity is illustrated by blocking the antibody binding.
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Discussion

General GHB use has risen dramatically over the last ten years. The use of GHB
in drug-facilitated sexual assaults has increased the public awareness of the abuses of this
drug. Because o f the rapid metabolism of GHB and the short time frame it is present in
the body, detection o f the drug is very difficult. This has caused difficulties for clinics,
forensic crime-iabs, and general law enforcement in determining the overall prevalence
of GHB use in sexual assault cases. This study examines potential surrogate markers that
may be developed to improve the window of detection for GHB.
Epiregulin and P ea-15 were worthy of note because of their high levels of
expression 24 hours after GHB exposure in the microarrays. The fact that 48 hours after
injection both still had large increases over control made them candidates for further
study. Neither Epiregulin nor Pea-15 was up regulated in microarrays performed with
RNA from the brain on GHB dosed mice (data not shown). The idea that these genes
were only activated in the blood is an important aspect of the development of a surrogate
marker. It suggests that the event being measured in blood is indirectly related to the
pathology. The fact that this effect takes time to develop and lasts for at least 48 hours
works to our benefit. It rules out that the increased P ea-15 or Epiregulin production
originated in the brain and escaped into systemic circulation. This is highly unlikely but
the mechanism behind this increase in protein levels is not understood.
Epiregulin is a mem ber of the epidermal growth factor (EGF) family (Toyoda et
al., 1995). This protein was initially purified from media excreted from NIH3T3/clone
T7, a mouse fibroblast-derived tumor cell line. The gene is mainly expressed in the
placenta and on peripheral blood leukocytes in normal human tissues (Toyoda et al..
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1997). Overall, the expression level of epiregulin is low in normal adult tissues. It is also
expressed in many different tumor cell lines. The highest levels of expression were in the
bladder (T-24), lung (A-549), kidney (ACHN and TR-24), colon (Colo201 and HCT-15),
and epiderm al (HeLa and KB) carcinoma lines (Toyoda et al., 1997).
Various functional assays have suggested that epiregulin is a cell-signaling
mediator that is involved in many biological systems. Originally thought to only act as a
growth-inhibitor factor, epiregulin was later proven to act as a mitogen in some cell
types. Its functions include a role in reproduction, liver regeneration, and as a vascular
smooth muscle cell mitogen (Das et al., 1997; Park et al., 2004; Sekiguchi et al., 2002;
Toyoda et al., 1997; Toyoda et al., 1995). Epiregulin expression is closely tied to bladder
cancer survivors, but expression is also upregulated and active in the developm ent of
pancreatic and prostate cancer (Thogersen et al.. 2001; Torring et al., 2000; Zhu et al.,
2000). The expression of epiregulin is not needed in the development of intestinal
tumors, but it is required for protection from intestinal damage (Lee et al., 2004).
Epiregulin is a target molecule involved in tumorgenesis in Ki-Ras-mediated signaling in
colon cancer cells (Baba et al., 2000). It has also been shown to be important in the
immortalization of human fibroblasts by telomerase (Lindvall et al., 2003). Recently,
epiregulin was found to play a role in the inflammatory response of kératinocytes and
macrophages (Shirasawa et al., 2004).
The epiregulin protein is found in a membrane-bound form and also as a mature
secreted form (Baba et al., 2000). The majority of the research conducted to date has
focused on the mature form o f the protein in the cytoplasm and later, as a type of
cytokine through secretion. The m embrane-bound epiregulin seems to act as a
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proinflam m atory cytokine that is produced in macrophages (Shirasawa et ah, 2004). This
shows that the soluble form and the membrane-bound form may have distinct functions.
Phosphoprotein enriched in astrocytes 15 (P ea-15) is a 15 kDa protein that was
originally identified as an abundant protein located in the cytoplasm of brain astrocytes
(Araujo et aL, 1993). P ea-15 was later shown to be expressed in a wide range of tissues
and to be conserved in various mammals (Danziger et al., 1995; Estelles et al., 1996;
Ramos et al., 2000). P ea-15 structurally contains a N-term inal death effector domain
(DBD) and a C-terminal tail. It exists in three isoforms based on phosphorylation state. It
can be present containing zero (N), one (Pa), or two (Pb) phosphorylated serine sites. The
Pa isoform is phosphorylated (S erine-116) via calcium -calm odulin Kinase II, while
protein kinase C controls the phosphorylation of the Pb (Serine 104) (Kubes et al., 1998).
M any studies have shown that Pea-15 regulates multiple cellular functions
through various interactions. It has been shown that P ea-15 can bind to Fas associated
death dom ain (FADD) and caspase-8. This results in the decrease of tumor necrosis
factor- alpha (TNF) triggered apoptosis in astrocytes (Estelles et al., 1999; Kitsberg et al.,
1999). P ea-15 also decreases Fas-induced apoptosis in fibroblasts (Condorelli et al,,
1999). P ea-15 activates the extracellular signal receptor-activated kinase (ERK) MAP
kinase pathway through Ras as well (Ramos et al., 2000). This function may serve to link
the apoptotic pathways and the ERK MAP kinase pathway. P ea-15 also modifies ERK
signaling by binding it in the nucleus and transporting it back into the cytoplasm
(Formstecher et al., 2001). This limits the cell’s ability to enter into the cell cycle.
The level of gene expression changes between the microarray and the RT-PCR
analyses are very different with both Epiregulin and P ea-15. GHB induced increases in
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Epiregulin expression 19.2 fold in the microarray, while expression was increased only
1.7 fold with the RT-PCR assay. P ea-15 expression was increased 20.9 fold in the
microarray, but just 4.8 fold in the RT-PCR assay. There are some potential explanations
for this large difference. The assays that measure these expression changes are very
different. M icroarrays involve hybridization of labeled cDNA to 50 base pair
oligonucleotides probes. The m icroarray is based on the hybridization of the
oligonucleotides to some internal region of the gene, while the RT-PCR assay is
dependent on two independent oligonucleotides binding to the ends of the cDNA. The
regions of the genes detected by the microarray oligonucleotides may have been better
represented and more accessible for binding than those of the RT-PCR primers.
There was no statistically significant increase in Epiregulin RT-PCR product from
GHB to control. There was a 1.6-fold increase on day 1 but because of a high standard
error of the mean this increase fell below a significant change (p<0.08). P ea-15 RT-PCR
levels were increased 4.8 fold on dayl and 3.3-fold by day 2 in GHB-treated mice over
control. W hile these increases are not as great as the increases by microarray, they do
confirm that these genes are upregulated and increased transcription is detectable in
peripheral blood.
Since future research goals include developing an assay for the detection of GHB
exposure, determ ining the protein levels are the most important aspect of these studies.
The increases o f the Epiregulin and P ea-15 protein in GHB-treated mice over control are
imperative. These increases represent significant protein changes that are easily
measured. It is not known whether these changes represent a “mechanism” biomarker of
GHB exposure. It would be very interesting to determine if these alterations are the result

of random gene expression changes caused from GHB treatment or actual downstream
effects induced from the drug.
There are no know n data or m echanisms that connects epiregulin and GHB.
Studies have been done that make a case for a possible connection. Epiregulin expression
is induced by follicle-stim ulating hormone (FSH), which causes ovarian cell proliferation
(Sekiguchi et al., 2002). Epiregulin also acts as a mediator of luteinizing hormone (LH)
action in m am m alian ovulatory follicles (Freimann et al., 2004). It has also been found
that LH stim ulation induces the expression of epiregulin in mouse ovaries (Park et al.,
2004). It is widely accepted that both FSH and LH are regulated by gonadotropinreleasing horm one (GnRH). Since there is a direct link of epiregulin involvement with
these gonadotropin horm ones in ovarian cells there may be a relationship between
epiregulin and horm onal changes in other biological systems. It is accepted that GHB can
directly increase hum an growth hormone in both humans and mice (Van Cauter et al.,
1997; Volpi et al., 2000; Volpi et al., 1997). It may be that the endocrine system, via the
release of hormones in the pituitary gland is the mechanism that explains the increase of
epiregulin in peripheral blood after GHB exposure (Figure 10).
There is also very little data that elucidates a relationship between Pea-15 and
GHB. A gonadotropin-releasing hormone (GnRH) agonist, leuprolide acetate, reduces the
expression of Pea-15 by 50% in uterine leiom yomas (Bifulco et al., 2004). Leuprolide
acetate contains anti-proliferative properties that reduce the leiomyoma volume. This is,
in part, by suppressing the anti-apoptotic effects of Pea-15. GHB is known to increase the
concentration of grow th hormone, which can also decrease the rate of apoptosis (Baixeras
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et al., 2001; Jeay et al., 2000). It is not known whether these mechanisms are connected
(Figure 11).
There is the potential that the information found in this study could be developed
as a protein-based detection system for GHB use. Biomarkers are becoming increasingly
im portant in the field o f drug detection when there are issues involving their direct
measurement. Instead of detecting the drug itself, surrogate markers, resulting in directly
from the GHB exposure, would be detected. Biomarkers should accurately reflect the
amount o f GHB exposure over time. Both Epiregulin and P ea-15 protein levels are
increased in this model. An important aspect of this study is that these increases are
longer than the current detection limit of GHB using available techniques, which is
around 12 hours. The developm ent of an assay that can measure these proteins easily in a
flow cytom eter instrument is very advantageous based on the availability of these
instruments in hospitals and clinics. It is also important that we have two independent
markers. We have yet to validate the additional genes that were also up or down regulated
by GHB. A successful assay may need to possess an optimal combination of multiple
biomarkers as this could increase sensitivity and decrease false-positives.
Many future experim ents would be needed to make sure these results are a
specific response to GHB exposure. One of these experiments would include comparing
Epiregulin and P ea-15 levels in DBA/2J mice against combinations of GHB, GAB A, and
the respective antagonists (NCS-382 and CGP-35348). This information would determine
if the changes in protein levels are specific for GHB or give an indication that these
changes are a by-product o f complex relationship between the GABAergic and GHB
systems. After determ ining which system these changes may be directed through, the
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next step would be to determine if they are related to the dopaminergic or cholinergic
systems. Both GHB and GABA affect these neurotransm itter levels and involvem ent of
these m olecules would be the most logical mechanism. Another study would need to
compare Epiregulin and P ea-15 protein levels after exposure to other drugs of abuse. A
com parison among other CNS depressant drugs such as benzodiazepines, barbiturates
and alcohol would be useful. It is known that neither Epiregulin nor P ea-15 RNA
expression levels are increased in microarray assays after a Ig/kg dose of ethanol (data
not shown), but no protein information is available. Further development of this type of
detection system would be to move from the current mouse model to a human model.
Human baseline levels of Epiregulin and P ea-15 in peripheral blood would need to be
determined. There are also no data on how tightly these genes are regulated in human
white blood cells. There are many difficulties with this type of study that include getting
approval for administering a schedule 1 drug to humans. Also vital would be to determine
the influence of different variables such as age, sex, and ethnicity on the validity of the
biomarkers.
In conclusion, this study begins the process needed to uncover and validate
potential biomarkers that are specific to GHB exposure. Future work may provide an
alternative testing system that would provide investigators with a longer tim efram e for
GHB detection.
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Figure 10. Potential mechanism linking Epiregulin and GHB.
GHB is know n to affect the release of growth hormone and also directly control multiple
neurotransm itters that influence the endocrine system. Epiregulin is also tied into the
endocrine system, mostly through the maturation and proliferation of ovary cells.
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Figure 11. Potential mechanism linking Pea-15 and GHB

GHB is known to increase the release of growth hormone and also affect multiple
neurotransm itters that influence the endocrine system. P ea-15 and growth hormone have
been proven to act as inhibitors of apoptosis.
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